Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Abivax SA ( (FR:ABVX) ) just unveiled an update.
Abivax SA announced a webcast scheduled for March 17, 2025, featuring Dr. David Rubin, a leading gastroenterologist, who will discuss treatments for ulcerative colitis and present insights on Abivax’s phase 3 ABTECT trial evaluating obefazimod. This trial aims to address unmet medical needs in ulcerative colitis treatment, potentially impacting Abivax’s industry positioning and offering significant insights for stakeholders.
More about Abivax SA
Abivax is a clinical-stage biotechnology company dedicated to developing therapeutic products that utilize the body’s natural regulatory mechanisms to stabilize immune responses in patients with chronic inflammatory diseases. With operations in France and the United States, the company’s primary focus is on obefazimod, a lead drug candidate currently in phase 3 clinical development for treating moderately to severely active ulcerative colitis.
YTD Price Performance: -1.33%
Average Trading Volume: 976
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €432.8M
Learn more about ABVX stock on TipRanks’ Stock Analysis page.
